228 related articles for article (PubMed ID: 12021893)
1. Molecular prognostic markers in pancreatic cancer.
Ghaneh P; Kawesha A; Evans JD; Neoptolemos JP
J Hepatobiliary Pancreat Surg; 2002; 9(1):1-11. PubMed ID: 12021893
[TBL] [Abstract][Full Text] [Related]
2. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.
Sakorafas GH; Tsiotou AG; Tsiotos GG
Cancer Treat Rev; 2000 Feb; 26(1):29-52. PubMed ID: 10660490
[TBL] [Abstract][Full Text] [Related]
3. [Recent advances in gene change of pancreatic cancer].
Wang YY; Cui QC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):79-82. PubMed ID: 15052782
[TBL] [Abstract][Full Text] [Related]
4. Genetic pathways of two types of gastric cancer.
Tahara E
IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
[TBL] [Abstract][Full Text] [Related]
5. Role of growth factors in pancreatic cancer.
Korc M
Surg Oncol Clin N Am; 1998 Jan; 7(1):25-41. PubMed ID: 9443985
[TBL] [Abstract][Full Text] [Related]
6. Survivin expression and its clinical significance in pancreatic cancer.
Lee MA; Park GS; Lee HJ; Jung JH; Kang JH; Hong YS; Lee KS; Kim DG; Kim SN
BMC Cancer; 2005 Oct; 5():127. PubMed ID: 16202147
[TBL] [Abstract][Full Text] [Related]
7. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
8. Molecular aspects of carcinogenesis in pancreatic cancer.
Koliopanos A; Avgerinos C; Paraskeva C; Touloumis Z; Kelgiorgi D; Dervenis C
Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):345-56. PubMed ID: 18693168
[TBL] [Abstract][Full Text] [Related]
9. Molecular diagnosis of pancreatic cancer.
Inoue S; Tezel E; Nakao A
Hepatogastroenterology; 2001; 48(40):933-8. PubMed ID: 11490843
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathology of pancreatic cancer.
Hruban RH; Iacobuzio-Donahue C; Wilentz RE; Goggins M; Kern SE
Cancer J; 2001; 7(4):251-8. PubMed ID: 11561601
[TBL] [Abstract][Full Text] [Related]
11. [New molecular targets in pancreatic cancer].
Torrisani J; Bournet B; Cordelier P; Buscail L
Bull Cancer; 2008 May; 95(5):503-12. PubMed ID: 18541514
[TBL] [Abstract][Full Text] [Related]
12. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis.
Bandoh N; Hayashi T; Takahara M; Kishibe K; Ogino T; Katayama A; Imada M; Nonaka S; Harabuchi Y
Cancer Lett; 2004 May; 208(2):215-25. PubMed ID: 15142681
[TBL] [Abstract][Full Text] [Related]
13. [Genetics of pancreatic cancer: recent advances in molecular diagnosis].
Hayashi N; Egami H; Ogawa M
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):476-81. PubMed ID: 12094699
[TBL] [Abstract][Full Text] [Related]
14. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer.
Zhang Y; Dang C; Ma Q; Shimahara Y
Oncol Rep; 2005 Jul; 14(1):161-71. PubMed ID: 15944784
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 overexpression induces epidermal growth factor-independent resistance to apoptosis linked to BCL-2 in human A431 carcinoma.
Rieber M; Rieber MS
Apoptosis; 2006 Jan; 11(1):121-9. PubMed ID: 16374552
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung.
Shabnam MS; Srinivasan R; Wali A; Majumdar S; Joshi K; Behera D
Lung Cancer; 2004 Aug; 45(2):181-8. PubMed ID: 15246189
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
19. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
20. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
